June 8, 2022 02:33 PM EDTUpdated 02:52 PM

Harvard, Kesselheim paper highlights almost 90x increase in launch prices for new drugs since 2008

Paul Schloesser

Associate Editor

With increasing clamor over rising prices and corresponding inaccessibility of certain drugs, the newest paper out of the Journal of the American Medical Association confirms …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Harvard, Kesselheim paper highlights almost 90x increase in launch prices for new drugs since 2008

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Har­vard, Kessel­heim pa­per high­lights al­most 90x in­crease in launch prices for new drugs since 2008

Paul Schloesser

Associate Editor

Sign up to read this article for free.

more like this

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Harvard, Kesselheim paper highlights almost 90x increase in launch prices for new drugs since 2008

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings